Combined Immunotherapy Promising in Advanced NSCLC, RCC MedPage Today, 27 Sep 2019 Adding an indoleamine 2, 3-dioxygenase 1 (IDO1) selective inhibitor to anti-programmed cell death protein (PD)-1 monoclonal…